The discussion highlights the differences between intranasal esketamine and intravenous ketamine, particularly in terms of dosing and ease of administration. While intranasal options may be more accessible for those averse to needles, intravenous dosing allows for more precise therapeutic levels. Additionally, the cost implications of both treatments are addressed, revealing that esketamine can be more expensive but often covered by insurance, whereas generic ketamine is typically less costly.
